MIAMI – April 18, 2018 – Legendary entertainer Don Francisco returns to the annual Hispanicize event this year to host an engaging and educational panel discussion: Let’s Learn Together with Don Francisco: Understanding the Facts about Type 2 Diabetes on April 18 at 11:00 a.m. ET. The panel discussion, presented by the Lilly and Boehringer Ingelheim Diabetes Alliance, is part of a larger initiative called Basado en Hechos, which was launched in 2017 to share facts about type 2 diabetes and help dispel common myths about diabetes care, including insulin treatment.
Don Francisco, who was first diagnosed 17 years ago, will open the discussion by sharing his personal story of living with type 2 diabetes, before moderating a conversation with two well-respected endocrinologists, Gaston M. Ponte M.D., C.C.D., F.A.C.E., Assistant Professor of Medicine, University of Central Florida and Dr. Rosemarie Lajara, President and Lead Endocrinologist for Diabetes America, Dallas, Texas. The panel is intended to discuss facts about type 2 diabetes, which affects an estimated 12.1 percent of U.S. Hispanics, and the importance of having conversations with healthcare providers to help those living with type 2 diabetes make informed decisions about their health [1]
“Shortly after being diagnosed, I realized I had a lot to learn about diabetes type 2 and how to take care of myself,” said Don Francisco. “With my own experiences and knowing of this condition’s impact especially within the Hispanic community I joined the Basado en Hechos initiative to help create awareness and educate our community on the importance of diabetes, and so that we take informed decisions on our health alongside our doctors. I’m really happy to return to Hispanicize and to work with two experts to share this important message.”
The panel discussion is open to anyone attending the Hispanicize event, and will take place in the Metropolitan Ballroom, 3rd floor, at the JW Marriott in Miami on April 18 at 11:00 a.m. ET. You can also join the conversation online via Facebook, Twitter and Instagram using hashtag #Hispz18.
“In my experience, I have seen firsthand the importance of educating my patients about type 2 diabetes, so I am excited to have the opportunity to join Don Francisco on stage at Hispanicize,” said Dr. Rosemarie Lajara, President and Lead Endocrinologist for Diabetes America, Dallas, Texas. “It is part of my job as a healthcare provider to support and arm my patients with information to help them understand that they can manage their type 2 diabetes so they can live their lives”
About Basado en Hechos
The panel discussion is a part of a larger nationwide initiative – Basado en Hechos, which launched in 2017 by Lilly and Boehringer Ingelheim in partnership with Don Francisco to help address common misconceptions about type 2 diabetes and insulin treatment in the Hispanic population.
About Diabetes
Approximately 29 million Americans and an estimated 415 million people worldwide have diabetes, and nearly 28 percent of Americans with diabetes — totaling eight million people — are undiagnosed.[2,3] In the U.S., approximately 12 percent of those aged 20 and older have diabetes[2]. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diagnosed adult diabetes cases in the U.S.[2] Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin.
Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in diabetes that centers on compounds representing several of the largest diabetes treatment classes. The alliance leverages the strengths of two of the world’s leading pharmaceutical companies. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Find out more about the alliance at www.boehringer-ingelheim.co
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly
About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. Please visit our website to learn more about how we make more health for more people through our Corporate Social Responsibility initiatives.
In 2016, Boehringer Ingelheim achieved net sales of about $17.6 billion (15.9 billion euros). R&D expenditure corresponds to 19.6 percent of its net sales.
For more information please visit www.boehringer-ingelheim
About Hispanicize
Now in its ninth year, Hispanicize 2018 (www.HispanicizeEvent.com) (#Hispz18) is the iconic, largest annual event for Latino trendsetters and newsmakers in digital content creation, journalism, marketing, entertainment and tech entrepreneurship.
Hispanicize 2018 is expected to gather more than 3,000 of the nation’s most influential Latino professionals from the industries of digital content creation, journalism, music, marketing, film and business over four days. The event will take place in downtown Miami’s JW Marriott Marquis Hotel, April 17-19, 2018.
The Hispanicize event is a launch pad for creative endeavors, new products, technologies, marketing campaigns, films, books, music and more targeting Latinos in the U.S. and/or Puerto Rico.The Hispanicize event is owned and operated by Hispanicize Media Group, LLC, the parent company of DiMe Media, Hispanic Kitchen and the Hispanic PR Blog.
The Hispanicize Event can be found Facebook https://www.facebook.com/Hispa
CONTACT:
Grant Smith
Lilly Diabetes
(317) 954-9907
grant.smith@lilly.com
Christopher Wahlers
Boehringer Ingelheim Pharmaceuticals, Inc.
Phone: (203) 798-4375
christopher.wahlers@boehringer
References
1. Statistics About (n.d.). Retrieved February 15, 2018, from http://www.diabetes.org/diabet
2. International Diabetes IDF Diabetes Atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015. Retrieved on April 27, 2017, fromhttp://www.diabetesatlas.org/r
3. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, Atlanta, GA: U.S. Department of Health and Human Services; 2014. Retrieved on April 27, 2017, from ˚
###
